Mirum Pharmaceuticals (MIRM) Return on Capital Employed (2019 - 2026)
Mirum Pharmaceuticals (MIRM) recorded quarterly Return on Capital Employed of 134.07% in Q1 2026, down 3583.39% quarter-over-quarter from 3.64% in Q4 2025, and down 12026.0% on a YoY basis from N/an in Q1 2025.
Mirum Pharmaceuticals (MIRM) Return on Capital Employed (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 134.07% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 12026.0% year-over-year to 134.07%; the TTM figure through Mar 2026 stood at 134.07% (down 12026.0% YoY), while the FY2025 annual figure was 4.02%, up 1245.0% from the prior year.
- Return on Capital Employed was 134.07% for Q1 2026 at Mirum Pharmaceuticals, down from 3.64% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 3.64% in Q4 2025 to a low of 134.07% in Q1 2026.
- Historically, Return on Capital Employed has averaged 34.42% across 5 years, with a median of 19.96% in 2024.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed surged 3521 bps in 2022, then sank 12026 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 44.65% in 2022, then jumped by 56 bps to 19.44% in 2023, then climbed by 17 bps to 16.14% in 2024, then surged by 77 bps to 3.64% in 2025, then slumped by 3583 bps to 134.07% in 2026.
- The last three Return on Capital Employed figures came in at 134.07% (Q1 2026), 3.64% (Q4 2025), and 7.02% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Mirum Pharmaceuticals | 6.29 Bn | 5.90 Bn | 131.08 Mn | -134.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134.07% |
| Dec 31, 2025 | -3.64% |
| Sep 30, 2025 | -7.02% |
| Jun 30, 2025 | -10.13% |
| Mar 31, 2025 | -13.80% |
| Dec 31, 2024 | -16.14% |
| Sep 30, 2024 | -17.49% |
| Jun 30, 2024 | -19.93% |
| Mar 31, 2024 | -19.96% |
| Dec 31, 2023 | -19.44% |
| Sep 30, 2023 | -23.44% |
| Jun 30, 2023 | -35.86% |
| Mar 31, 2023 | -42.68% |
| Dec 31, 2022 | -44.65% |
| Sep 30, 2022 | -51.05% |
| Jun 30, 2022 | -62.91% |
| Mar 31, 2022 | -62.95% |
| Dec 31, 2021 | -78.00% |
| Sep 30, 2021 | -86.26% |
| Jun 30, 2021 | -69.77% |